drugset
drugset / Trial / NCT02232490

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

NCT02232490 ↗

Phase 3 Unknown 120 enrolled Immunitor LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma.

Timeline

Start
2015-01
Primary completion
2019-11
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject hepcortespenlisimut-L Vaccine — —

Indications

hepatocellular carcinoma